

Dear Editor,

Thank you very much for your letter and advice. We have revised the manuscript, and would like to re-submit it for your consideration. We have addressed the comments raised by the reviewers, and the amendments are highlighted in red in the revised manuscript. Point by point responses to the reviewers' comments are listed below this letter.

We hope that the revised version of the manuscript is now acceptable for publication in your journal. I look forward to hearing from you soon. With best wishes.

Yours sincerely,

Jin Gu

1. Reviewer's 03093156

COMMENTS TO AUTHORS

Very interesting study. After some minor language revision, it can be accepted for publication.

Reply : The manuscript was revised by native speakers from *Editage English Language Editing Services*, and language certification was provided.

2. Reviewer's 03092961

COMMENTS TO AUTHORS

1 Some minor language polishing should be corrected.

- 2 The manuscript need some editing, maybe the editor of the journal can help.
- 3 The references list can be updated. Some more recent references can be added, and discussed.

Reply:

1. The manuscript was revised by native speakers from *Editage English Language Editing Services*, and language certification was provided.
2. The manuscript was edited as the editor instructed, the amendments were highlighted in red color.
3. Recent references (Ref. 29 and 30) were added. They were discussed in the DISCUSSION part in the main text highlighted in red.

“A recent study^[29] assessed HER2-amplification/overexpression in 1914 stage II-III and IV CRC patients. The result showed that HER2 was not associated with overall survival or progress free survival. A higher proportion of HER2-overexpressing cases experienced recurrence, but the difference was not significant. Nicola *et al* considered that HER2 status should be assessed as a putative biomarker of resistance to anti-EGFR therapy in KRAS wild-type patients^[30].”